Gerhard Schymik

Learn More
BACKGROUND Transcatheter aortic valve implantation was developed to mitigate the mortality and morbidity associated with high-risk traditional aortic valve replacement. The Edwards SAPIEN valve was approved for transcatheter aortic valve implantation transfemoral delivery in the European Union in November 2007 and for transapical delivery in January 2008.(More)
BACKGROUND Transcatheter aortic valve implantation was developed to provide a therapeutic option for patients considered to be ineligible for, and to mitigate mortality and morbidity associated with, high-risk surgical aortic valve replacement. METHODS AND RESULTS The Edwards SAPIEN Aortic Bioprosthesis European Outcome (SOURCE) Registry was designed to(More)
BACKGROUND Transapical transcatheter aortic valve implantation is generally perceived to be associated with increased morbidity compared with transfemoral transcatheter aortic valve implantation. We aimed to compare access-related complications and survival using propensity score matching. METHODS AND RESULTS Prospective, single-center registry of 1000(More)
OBJECTIVES To assess outcomes for patients undergoing transcatheter aortic valve implantation (TAVI) versus surgical aortic valve replacement but with less than high risk. BACKGROUND While there is abundant data for high risk patients there is insufficient data for reduced risk. METHODS Patients undergoing TAVI or SAVR between 2007 and 2012 in Karlsruhe(More)
BACKGROUND There is a lack of data on the comparative efficacy and procedural safety of open irrigated radiofrequency (RF) and cryoballoon catheter (CB) ablation for pulmonary vein isolation in patients with paroxysmal atrial fibrillation. METHODS AND RESULTS In a prospective, noninferiority study, 315 patients were randomly assigned to RF (n=159) or CB(More)
OBJECTIVES This study sought to determine the feasibility, safety, and exploratory efficacy of the Embrella Embolic Deflector (EED) system (Edwards Lifesciences, Irvine, California) in patients undergoing transcatheter aortic valve replacement (TAVR). BACKGROUND Few data exist on the value of using embolic protection devices during TAVR. METHODS This(More)
BACKGROUND This prospective study examines the impact of EuroSCORE and transfemoral (TF) or transapical (TA) delivery approach on mortality at 30 days and 1 year in patients with severe aortic stenosis implanted with either the Edwards SAPIEN Transcatheter Heart Valve (THV) or Medtronic CoreValve. METHODS AND RESULTS TAVI was successfully performed in 293(More)
The occurrence of new conduction abnormalities that lead to the requirement for new permanent pacemaker implantation (PPI) has been reported to be the most frequent complication following transcatheter aortic valve implantation (TAVI). However, the reasons and clinical significance of TAVI-induced conduction disturbances and PPI are yet to be fully(More)
Compared with surgical aortic valve replacement, transcatheter aortic valve implantation (TAVI) is associated with a higher risk of developing a new conduction disorder that necessitates permanent pacemaker implantation (PM). The most frequently observed conduction disorder is left bundle branch block (LBBB), which impairs left ventricular function. The(More)
OBJECTIVE The purpose of this article is to assess aortic root and iliofemoral vessel anatomy and the frequency of clinically significant incidental findings on aortoiliac CT angiography (CTA) performed for planning of transcutaneous aortic valve implantation. MATERIALS AND METHODS Aortoiliac CTA studies of 207 patients scheduled for transcutaneous aortic(More)